The Singapore-based startup Biobot has raised $24 million in Series B funding. The company specializes in robotic prostate biopsies and treatment options.
ZIG Ventures and the new strategic investors joined the round, which was led by Mr. Tony Tan.
Using the money, the company hopes to further improve its infrastructure for digital surgery and increase its global footprint.
Using cutting-edge technology, Biobot is committed to revolutionizing the urological standard of care. An improved visual aid and robotic precision for percutaneous transperineal treatments are offered to urologists by its flagship device, the iSR’obot Mona Lisa system.
With over 50 Mona Lisa robots deployed and over 20,000 surgeries conducted, the technology is already in use throughout the world.
